Dr Aditya Bardia

Go Back

Medical Oncologist

  • Harvard Medical School
  • location United States

Dr Aditya Bardia, a board-certified medical oncologist, is an Attending Physician at Massachusetts General Hospital (MGH), Associate Professor, Harvard Medical School, Boston. As the Director of Breast Cancer Research Program at MGH, Dr Bardia is interested in advancing research to improve the outcomes with breast cancer. Dr Bardia has led the clinical development of antibody drug conjugate (ADC), sacituzumab govitecan, the first ADC approved for patients with metastatic triple negative breast cancer. Dr Bardia has received several research awards including outstanding award for research excellence at Mayo Clinic, Young Investigator Award from ASCO, and Douglas Family Foundation prize for excellence in oncology research at MGH. Dr Bardia is the editor of precision medicine clinic section of The Oncologist, co-leader of the Molecular and Precision (MAP) tumor board at MGH, and editorial board member of ASCO molecular oncology tumor board.

Dr Aditya Bardia has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Consultant/Advisory board: Pfizer, Novartis, Genentech, Merck, Radius Health, Immunomedics/Gilead, Sanofi, Daiichi Pharma/Astra Zeneca, Eli Lilly, Mersana. Contracted Research/Grant (to institution): Genentech, Novartis, Pfizer, Merck, Sanofi, Radius Health, Immunomedics/Gilead, Daiichi Pharma/Astra Zeneca, Eli Lilly.

Programmes developed by Dr Aditya Bardia

tweetorial Tweetorial
Oncology 
Tweetorial video: Treating ER+/HER2-low metastatic breast cancer, 2L and beyond

Journey through a patient case from testing and diagnosis to treatment and AE management

Experts
Dr Aditya Bardia
Endorsed by
GRASP
  • clock 11 MIN
  • calendar Apr 2024

Educational programme supported by an Independent Educational Grant from Menarini Stemline Oncology.
eks
Experts Knowledge Share Video

Episode

2

of 4

episode
Oncology 
New Oral Endocrine Therapy Options for Patients with Advanced or Metastatic ER+ Breast Cancer

Episode 2: Optimisation of Treatment Selection & Sequencing Decisions in ER+/HER2- Advanced or Metastatic Breast Cancer

Experts
Dr Sara Tolaney, Dr Aditya Bardia, Prof. Frédérique Penault-Llorca
Endorsed by
SOLTI
GRASP
  • clock 14 MIN
  • calendar Jul 2023

Educational programme supported by an Independent Educational Grant from Menarini Stemline Oncology
video Video

Episode

3

of 4

episode
Oncology 
New Oral Endocrine Therapy Options for Patients with Advanced or Metastatic ER+ Breast Cancer

Episode 3: ESR1 Mutation: The Need for & Role of Testing in ER+/HER2- Advanced or Metastatic Breast Cancer

Experts
Dr Sara Tolaney, Dr Aditya Bardia, Prof. Frédérique Penault-Llorca
Endorsed by
SOLTI
GRASP
  • clock 20 MIN
  • calendar Jul 2023

Educational programme supported by an Independent Educational Grant from Menarini Stemline Oncology
video Video

Episode

4

of 4

episode
Oncology 
New Oral Endocrine Therapy Options for Patients with Advanced or Metastatic ER+ Breast Cancer

Episode 4: Panel Discussion and Summary

Experts
Dr Sara Tolaney, Dr Aditya Bardia, Prof. Frédérique Penault-Llorca
Endorsed by
SOLTI
GRASP
  • clock 19 MIN
  • calendar Jul 2023

Educational programme supported by an Independent Educational Grant from Menarini Stemline Oncology
video Video

Episode

1

of 4

episode
Oncology 
New Oral Endocrine Therapy Options for Patients with Advanced or Metastatic ER+ Breast Cancer

Episode 1: Overview of Clinical Data of SERDs & Their Place in Treatment Landscape

Experts
Dr Sara Tolaney, Dr Aditya Bardia, Prof. Frédérique Penault-Llorca
Endorsed by
SOLTI
GRASP
  • download Downloadable
    Resources
  • clock 18 MIN
  • calendar Jul 2023

Educational programme supported by an Independent Educational Grant from Menarini Stemline Oncology